| Private Placement / Financing Transactions
Merida Biosciences: The company raised $121 million of Series A venture funding in a deal led by Bain Capital Life Sciences, Third Rock Ventures and BVF Partners on April 8, 2025. GV and Perceptive Xontogeny Venture Fund also participated in the round. The company is a developer of biotherapeutics engineered to eliminate pathogenic autoantibodies for treating autoimmune diseases.
Pheast Therapeutics: The company raised $76 million of Series A venture funding in a deal led by Catalio Capital Management and ARCH Venture Partners on April 10, 2025, putting the company’s pre-money valuation at $54 million. Rsquared, Alexandria Venture Investments, and other undisclosed investors also participated in the round. The company is a provider of macrophage-targeted immunotherapies intended for cancer treatment.
Imbria Pharmaceuticals: The company raised $59.2 million of Series B venture funding from Cytokinetics, RA Capital Management and SV Health Investors on April 10, 2025, putting the company’s pre-money valuation at $65 million. AN Ventures, Deep Track Capital and Catalio Capital Management also participated in the round. The company is an operator of a clinical-stage business developing novel therapies for patients with life-altering cardiometabolic disorders.
Solu Therapeutics: The company raised $40 million of Series A venture funding from Astellas Venture Management, Eli Lilly and Company and Hengdian Group Capital (HgC) on April 9, 2025, putting the company’s pre-money valuation at $61 million. Biovision Ventures, Pappas Capital, Alexandria Venture Investments, Leukemia & Lymphoma Society, Santé Ventures, Longwood Fund and DCVC Bio also participated in the round. The company is a developer of bifunctional small-molecule therapeutics designed to eliminate disease-driving cells.
Stramsen Biotech: The company raised $25 million of venture funding in a deal led by Global Emerging Markets on April 7, 2025. The company is a developer of a clinical-stage Biotechnology business that is developing innovative therapeutics for the treatment of different kinds of infectious and noninfectious diseases.
Chemeleon: The company raised $10 million of Series A venture funding from undisclosed investors on April 10, 2025. The company is a developer of a chemical sensor designed to rapidly detect chemical compounds.
Vaxess Technologies: The company raised $9 million of venture funding from Engine Ventures and RA Capital Management on April 9, 2025. The company is a developer of novel therapies designed to help in oncology care and infectious diseases.
ImmunoMet: The company raised KRW 11.9 billion of venture funding from Samsung Electronics on April 8, 2025, putting the company’s pre-money valuation at KRW 55.5 billion. The company is a developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients.
Lytica Therapeutics: The company raised $7.8 million of venture funding in the form of convertible debt from Standish Spring Investments and other undisclosed investors on April 9, 2025. The company is an operator of a biotechnology business that is developing novel peptide conjugates for next-generation Antibody-Drug Conjugates (ADCs).
Olaris: The company raised an undisclosed amount of Series B venture funding from Labcorp Venture Fund, Northpoint Capital Group and Growth Capital on April 11, 2025. Innospark Ventures, Alumni Ventures and Robert Carpenter also participated in the round. The company is a developer of a precision medicine platform for therapeutic selection, treatment response monitoring, disease diagnosis, and target identification across various therapeutic areas, including oncology, solid-organ transplant, and neurodegeneration.
Thoughtful.ai: The company raised an undisclosed amount of venture funding from New Mountain Capital on April 10, 2025. The company is a developer of an artificial intelligence operating system designed for healthcare revenue cycle management teams.
|
